The law says medical cannabis is legal in the UK. The reality says something different. Since November 2018, specialist doctors have been permitted to prescribe cannabis-based medicines for a range of conditions. Yet in 2026, the vast majority of patients who could benefit from these treatments cannot access them through the NHS. The gap between legal entitlement and practical access has become the defining feature of the UK medical cannabis programme — and patients are paying the price.
The cost barrier
For Sarah, a 42-year-old from Manchester with fibromyalgia, the maths is simple and brutal. Her private clinic charges £200 for an initial consultation and £75 for each follow-up. Her monthly prescription for a CBD-dominant oil costs £180. Her GP, who manages the rest of her healthcare, cannot prescribe cannabis because only specialist clinicians are authorised to do so under current guidelines. The result is a parallel system: one doctor for cannabis, another for everything else.
"I was bedridden before I started treatment," Sarah says. "The pain was so bad I could not hold my children. Cannabis gave me my life back. But I am paying £255 a month just to function. If I lose my job, I lose my medicine. That fear never goes away."
Sarah's story is not unusual. Across the UK, an estimated 100,000 patients hold private medical cannabis prescriptions. Many more — potentially over a million — self-medicate with illicit cannabis because they cannot afford private treatment. The cost barrier is not a side effect of the system. It is the system.
The geography of access
Cost is only part of the story. Geography plays an equally damaging role. The UK's private medical cannabis clinics are concentrated in London and the South East, with a scattering in Manchester, Birmingham, and Leeds. Patients in rural areas, in Wales, in the North East, and in Northern Ireland face long journeys or rely on telemedicine — itself a relatively recent development that not all clinics offer.
The situation is worse for NHS patients. The few NHS prescriptions that are issued come from specialist centres — typically epilepsy and multiple sclerosis clinics attached to teaching hospitals. A patient in Cornwall or the Highlands may be hundreds of miles from the nearest specialist who can legally prescribe cannabis-based medicines. The postcode lottery that plagues much of the NHS is amplified in medical cannabis, where specialist availability is the bottleneck.
The prescribing puzzle
Why are NHS prescriptions so rare? The answer lies in a tangle of guidelines, incentives, and institutional caution. NICE guidance, which clinicians rely on to make prescribing decisions, does not recommend cannabis-based medicines for chronic pain — the condition for which most patients seek treatment. NICE's position is that the evidence base is insufficient. This is true in the narrow sense that large-scale randomised controlled trials are limited, but it ignores the real-world evidence accumulated by thousands of patients who have found relief through private prescriptions.
The result is a Catch-22. NHS doctors will not prescribe without NICE approval. NICE will not approve without more evidence. And the evidence base grows slowly because the Schedule 1 classification of cannabis — which the Home Office is currently reviewing — makes research expensive and bureaucratically complex.
What needs to change
The fixes are not mysterious. Patient advocates, clinicians, and policy experts have been making the same recommendations for years. First, NICE must update its guidance to reflect the growing body of real-world evidence. Second, prescribing rights should be extended to GPs, not limited to specialists. Third, the NHS should fund medical cannabis prescriptions for conditions where private treatment has demonstrated efficacy. Fourth, the cost of private treatment should be reduced through domestic cultivation and streamlined licensing.
None of these reforms are radical. All of them have been implemented in other countries with medical cannabis programmes. Germany, which legalised medical cannabis the same year as the UK, allows GPs to prescribe and health insurance to cover the cost. The result: over 100,000 German patients receive medical cannabis through their health insurance, compared to fewer than five NHS prescriptions per month in the UK.
The human cost of delay
Behind every statistic is a patient. James, a 35-year-old veteran from Leeds, uses cannabis to manage PTSD after three tours in Afghanistan. He tried conventional medication — SSRIs, benzodiazepines, cognitive behavioural therapy. Nothing worked. Cannabis quietened the nightmares and gave him the stability to hold down a job. But he cannot afford a private prescription, so he buys from the illicit market, risking prosecution and consuming a product of unknown quality and potency.
"I served my country," James says. "I came back broken. The NHS gave me pills that made me worse. Cannabis is the only thing that helps, and I have to buy it from a dealer. How is that acceptable?"
It is not acceptable. The UK has a legal medical cannabis programme that serves a tiny fraction of the patients who need it. The rest are left to self-medicate, pay exorbitant private fees, or go without. Bridging this gap requires political will, regulatory reform, and a willingness to treat cannabis as what it is: a medicine that works for many patients who have exhausted other options.
The Home Office licensing review is a start. But until NICE updates its guidance, GPs are allowed to prescribe, and the NHS funds treatment, the gap between law and reality will continue to widen. Patients deserve better than a system that legalises their medicine and then makes it impossible to obtain.
